In conclusion, we have further refined the Tab2/ERα interaction, providing structural data that can be exploited as a potential drug target for overcoming Tam resistance in breast cancer cells or translated to other contexts in which activation of the inflammatory pathway cross-talks and interferes with the response to steroid hormones. This evidence concerns the gene ERAL1 and breast carcinoma.